Introduction: Myelofbrosis (MF) is often characterized by a multifactorial anemia determined, in part, by bone marrow (BM) fbrosis, extramedullary erythropoiesis and splenomegaly. Ruxolitinib (RUX) is the frst-in-class janus kinase 2 (JAK2) inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. The red cell distribution width (RDW) is the measure of erythrocyte volume variability (anisocytosis). RDW has been recognized as a marker of clinical and subclinical systemic infammation, and its elevation has also been associated with poor outcome in a wide spectrum of benign disorders and in different types of neoplasms. Methods: We retrospectively evaluated RDW in a single-center series of 200 consecutive patients with primary and secondary MF at RUX treatment initiation and examined any possible correlation with adverse MF features or drugrelated anemia and any prognostic impact. Results: We suggested 20.5% as the optimal cutoff point in RDW values at start of RUX to dichotomize patients in receiver operating characteristic (ROC) analysis for spleen response and for survival. Higher RDW values at RUX start were associated with clinical and laboratory features of an aggressive MF phenotype. Lower spleen response (p < 0.001) and greater odds of drug-related anemia at 3 (p=0.006) and 6 months (p < 0.001) were also seen in patients with higher RDW. Both increased RDW (considered as a continuous variable) and RDW≥20.5% were associated with shorter overall survival (OS) from RUX initiation in univariate and multivariate analysis: HR 1.25 (95% confdence interval [CI], 1.12–1.40) (p<0.001) and HR 3.01 (95% CI 1.81–4.99) (p<0.001), respectively. RDW≥20.5% at RUX start seems to possibly improve patients’ sub-stratifcation along with anemia and conventional prognostic scoring systems. Conclusions: RDW at RUX start might represent a good indirect measure of MF features and might have prognostic signifcance for RUXtreated patients affected by MF, aiding in the rapid detection of patients with poor prognosis.

Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib / Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria L.; Martelli, Maurizio; Breccia, Massimo. - In: ONCOLOGY AND THERAPY. - ISSN 2366-1070. - (2025). [10.1007/s40487-024-00322-2]

Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib

Laganà, Alessandro
Primo
;
Scalzulli, Emilia;Carmosino, Ida;Bisegna, Maria L.;Martelli, Maurizio;Breccia, Massimo
2025

Abstract

Introduction: Myelofbrosis (MF) is often characterized by a multifactorial anemia determined, in part, by bone marrow (BM) fbrosis, extramedullary erythropoiesis and splenomegaly. Ruxolitinib (RUX) is the frst-in-class janus kinase 2 (JAK2) inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. The red cell distribution width (RDW) is the measure of erythrocyte volume variability (anisocytosis). RDW has been recognized as a marker of clinical and subclinical systemic infammation, and its elevation has also been associated with poor outcome in a wide spectrum of benign disorders and in different types of neoplasms. Methods: We retrospectively evaluated RDW in a single-center series of 200 consecutive patients with primary and secondary MF at RUX treatment initiation and examined any possible correlation with adverse MF features or drugrelated anemia and any prognostic impact. Results: We suggested 20.5% as the optimal cutoff point in RDW values at start of RUX to dichotomize patients in receiver operating characteristic (ROC) analysis for spleen response and for survival. Higher RDW values at RUX start were associated with clinical and laboratory features of an aggressive MF phenotype. Lower spleen response (p < 0.001) and greater odds of drug-related anemia at 3 (p=0.006) and 6 months (p < 0.001) were also seen in patients with higher RDW. Both increased RDW (considered as a continuous variable) and RDW≥20.5% were associated with shorter overall survival (OS) from RUX initiation in univariate and multivariate analysis: HR 1.25 (95% confdence interval [CI], 1.12–1.40) (p<0.001) and HR 3.01 (95% CI 1.81–4.99) (p<0.001), respectively. RDW≥20.5% at RUX start seems to possibly improve patients’ sub-stratifcation along with anemia and conventional prognostic scoring systems. Conclusions: RDW at RUX start might represent a good indirect measure of MF features and might have prognostic signifcance for RUXtreated patients affected by MF, aiding in the rapid detection of patients with poor prognosis.
2025
myelofbrosis; ruxolitinib; red blood cell distribution width; overall survival; drug-induced anemia; spleen response
01 Pubblicazione su rivista::01a Articolo in rivista
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib / Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria L.; Martelli, Maurizio; Breccia, Massimo. - In: ONCOLOGY AND THERAPY. - ISSN 2366-1070. - (2025). [10.1007/s40487-024-00322-2]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1731591
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact